Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.33 |
| ▸ | HTR2C | P28335 | 6/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8435327 | 0.95 | NCF1 (0.39) | NCF1HTR2AHTR2CJAK2L3MBTL1 | |
| SCHEMBL25105751 | 0.93 | JAK2 (0.38) | NCF1HTR2AHTR2CJAK2PYGL | |
| SCHEMBL25105750 | 0.93 | JAK2 (0.38) | NCF1HTR2AHTR2CJAK2PYGL | |
| SCHEMBL25105756 | 0.93 | JAK2 (0.38) | NCF1HTR2AHTR2CJAK2PYGL | |
| SCHEMBL14302735 | 0.90 | NCF1 (0.33) | NCF1JAK2 | |
| SCHEMBL17888490 | 0.87 | HTR2A (0.40) | NCF1HTR2AHTR2CL3MBTL1MEN1 | |
| SCHEMBL8442130 | 0.85 | HTR2A (0.41) | NCF1HTR2AHTR2CL3MBTL1MEN1 | |
| SCHEMBL8257091 | 0.84 | HRH3 (0.32) | HTR2AHTR2CMCHR1 | |
| SCHEMBL18136205 | 0.82 | — | — | |
| SCHEMBL81996 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966164-B1 | NOVEL SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-06 | — | — | EP | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | MCHR1, MCHR2, MC1R | NCF1 834/4885HTR2A 394/4885HTR2C 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.